Drug Profile
Dornase alfa biobetter - Pharmsynthez/Xenetic Biosciences
Alternative Names: Bronchozym; Bronchozyme; Polysialylated DNase; PSA-DNase; PulmoXenLatest Information Update: 21 Sep 2020
Price :
$50
*
At a glance
- Originator Pharmsynthez; Xenetic Biosciences
- Developer Pharmsynthez
- Class Antifibrotics; Biobetters; Recombinant proteins
- Mechanism of Action Deoxyribonuclease 1 stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Cystic fibrosis